Volume 17

  • No. 4 December 2023
    In this issue...

    • Top 20 biopharma deals of 2023

    • Live forever: approaches to reverse aging

    • What are the drivers behind CNS deal flow?

    • Oligonucleotide therapies broaden their reach

    • Make way for gene editing

  • No. 3 September 2023
    In this issue...

    • Uncovering oncology’s dealmaking trends

    • M&A deals of 2023 so far"

  • No. 2 June 2023
    In this issue...

    • What’s next for vaccine technologies?

    • Dealmaking for nucleic-acid-based therapies

    • Sealing biopharma deals with molecular glues

    • The companies shaping AI-driven biopharma R&D

    • Leveraging AI tools with IBM for drug discovery

    • The licensing deal formula

  • No. 1 April 2023
    In this issue...

    • Molecular diagnostics: deals in focus

    • Navigating the oncology deal landscape